California, 3 Aug, 2023 (GNP): A groundbreaking “cancer-killing” drug named AOH1996 has emerged from early research, offering hope in the fight against solid tumors while sparing healthy cells.
Developed over two decades in partnership with the esteemed cancer research and treatment organization, City of Hope, in the United States, AOH1996 targets a cancerous form of the protein PCNA, crucial in DNA replication and tumor growth.
This promising drug is currently undergoing pre-clinical research, raising expectations for targeted and effective cancer treatment for patients.
Notably, Professor Linda Malkas, who has been at the forefront of this drug’s development, compared PCNA to a busy airline terminal with multiple gates. Conversely, AOH1996 effectively halts tumor cell growth by selectively targeting the altered form of PCNA found in tumor cells.
While the research has thus far demonstrated success in suppressing tumor growth in cell and animal models, the initial results are highly encouraging.
The drug’s first-phase clinical trial has commenced, evaluating its efficacy in humans. Remarkably, it has displayed effectiveness against cells derived from various cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers.
The significance of this breakthrough lies in the fact that PCNA was previously deemed “undruggable.” This advancement holds the potential to pave the way for more personalized and targeted cancer treatments in the near future.
The City of Hope, in collaboration with research partners, actively commits to advancing the development of AOH1996 swiftly for the benefit of cancer patients worldwide.
As the journey towards transforming cancer treatment unfolds, researchers, healthcare professionals, and patients eagerly anticipate the dawn of a new era in the battle against cancer.